Pastel BioScience
Startup developing a proteomics discovery and validation platform that combines engineered capture reagents, microfluidics, surface chemistry, detection hardware and bioinformatics to identify and quantify large numbers of proteins with high sensitivity. The company is developing the system as a plug-and-play instrument for research, pharma and diagnostic applications and explores licensing of component technologies.
Industries
Nr. of Employees
small (1-50)
Pastel BioScience
Hove, England, United Kingdom
Products
Proteomics discovery and validation platform (instrument and bioinformatics)
An integrated system combining engineered capture reagents, microfluidic sample handling, surface chemistry, sensitive detection and bioinformatics for protein identification and quantification in a modular instrument format.
InVenio Capture Molecules
Proprietary capture molecules engineered for purpose based on a novel human protein scaffold, featuring randomized natural binding sites for high-affinity target selection.
Pastel BioScience Proteomics Platform
Plug and play instrumentation offering single-molecule sensitivity and complete proteome coverage.
uHTP Selection Technology Platform
An ultra high-throughput selection platform utilizing a combination of novel biochemistry and microfluidics for selecting capture molecules with correct affinity and specificity.
Proteomics discovery and validation platform (instrument and bioinformatics)
An integrated system combining engineered capture reagents, microfluidic sample handling, surface chemistry, sensitive detection and bioinformatics for protein identification and quantification in a modular instrument format.
InVenio Capture Molecules
Proprietary capture molecules engineered for purpose based on a novel human protein scaffold, featuring randomized natural binding sites for high-affinity target selection.
Pastel BioScience Proteomics Platform
Plug and play instrumentation offering single-molecule sensitivity and complete proteome coverage.
uHTP Selection Technology Platform
An ultra high-throughput selection platform utilizing a combination of novel biochemistry and microfluidics for selecting capture molecules with correct affinity and specificity.
Services
Out-licensing of engineered capture molecules (without reporter) for external applications, including research and potential therapeutic development.
Licensing or collaborative use of an ultra high-throughput selection platform for large-scale affinity reagent discovery.
Partnerships with instrument developers to progress commercialisation of an integrated proteomics instrument platform.
Out-licensing of engineered capture molecules (without reporter) for external applications, including research and potential therapeutic development.
Licensing or collaborative use of an ultra high-throughput selection platform for large-scale affinity reagent discovery.
Partnerships with instrument developers to progress commercialisation of an integrated proteomics instrument platform.
Expertise Areas
- Proteomics platform development
- Affinity reagent engineering and library selection
- Proteomics bioinformatics and algorithm development
- Microfluidics and assay miniaturization
Key Technologies
- Single-molecule protein detection
- Microfluidics for assay automation
- Surface chemistry for capture assays
- Engineered small-protein scaffold affinity reagents
News & Updates
Blog post noting a comprehensive list of proteomics resources compiled and published on the company website.
Article describing the company's development of an array-based proteomics platform that combines protein capture agents with detection workflows analogous to high-throughput sequencing platforms.
Media piece describing the technology's potential for early biomarker identification and its application to disease risk prediction.
Case study summarizing the company's epimer-based ligand selection technology and potential applications in diagnostics and therapeutics.
Announcement of an informal collaboration with an external instrument developer to progress the development and commercialisation of the proteomics platform.
Award of a proof-of-concept grant to demonstrate single-molecule detection and identification of target proteins for platform development.
Blog post noting a comprehensive list of proteomics resources compiled and published on the company website.
Article describing the company's development of an array-based proteomics platform that combines protein capture agents with detection workflows analogous to high-throughput sequencing platforms.
Media piece describing the technology's potential for early biomarker identification and its application to disease risk prediction.
Case study summarizing the company's epimer-based ligand selection technology and potential applications in diagnostics and therapeutics.
Announcement of an informal collaboration with an external instrument developer to progress the development and commercialisation of the proteomics platform.
Award of a proof-of-concept grant to demonstrate single-molecule detection and identification of target proteins for platform development.